Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Xtant Medical Holdings (XTNT) over the last 17 years, with Q3 2025 value amounting to $430000.0.

  • Xtant Medical Holdings' Capital Expenditures fell 7956.27% to $430000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 3009.99%. This contributed to the annual value of $4.1 million for FY2024, which is 18248.63% up from last year.
  • Xtant Medical Holdings' Capital Expenditures amounted to $430000.0 in Q3 2025, which was down 7956.27% from $366000.0 recorded in Q2 2025.
  • In the past 5 years, Xtant Medical Holdings' Capital Expenditures ranged from a high of $2.1 million in Q3 2024 and a low of $223000.0 during Q3 2023
  • In the last 5 years, Xtant Medical Holdings' Capital Expenditures had a median value of $484000.0 in 2022 and averaged $601842.1.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 84349.78% in 2024, then crashed by 7956.27% in 2025.
  • Xtant Medical Holdings' Capital Expenditures (Quarter) stood at $626000.0 in 2021, then fell by 29.23% to $443000.0 in 2022, then decreased by 18.06% to $363000.0 in 2023, then soared by 85.12% to $672000.0 in 2024, then plummeted by 36.01% to $430000.0 in 2025.
  • Its Capital Expenditures stands at $430000.0 for Q3 2025, versus $366000.0 for Q2 2025 and $1.2 million for Q1 2025.